Enzymotec Announces Signing Of Final Settlement And License Agreement With Neptune Technologies & Bioressources Inc.
Published: Apr 28, 2014
MIGDAL HA'EMEQ, Israel, April 28, 2014 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that it signed a final settlement and license agreement with Neptune Technologies & Bioressources Inc. (Nasdaq:NEPT) ("Neptune") and Acasti Pharma Inc. ("Acasti"). The International Trade Commission's ("ITC") investigation and related U.S. federal court actions will be terminated and dismissed accordingly.
Help employers find you! Check out all the jobs and post your resume.